Abstracts tagged "Damage Index"

Abstract Number: 0511 • ACR Convergence 2025
Submandibular Gland Ratio Stratifies Salivary Function and Reveals a Senescence Peak in Anti-SSA Positive Sjögren’s Syndrome
Chiao-Feng Cheng¹, Tseng-Cheng Chen², Min-Shu Hsieh³, TING-YUAN LAN⁴, Jui-Hung Kao⁵, Yu Heng Lin⁶, Mei-Fang Cheng⁷, Yi-Chieh Chen⁸, Hsiao-Sang Chu⁹, Yi-Min Huang¹⁰, Cheng-Hsun Lu¹¹, Ko-Jen Li¹¹, Chieh-Yu Shen¹ and Song-Chou Hsieh¹², ¹Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ²Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ³Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei ¹⁰⁰²²⁵, Taiwan, Taipei, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁵Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁶Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan, Taipei, Taiwan (Republic of China), ⁷Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁸Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁹Department of Ophthalmology, National Taiwan University Hospital, Taipei City, Taiwan., Taipei, Taiwan (Republic of China), ¹⁰Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ¹¹National Taiwan University Hospital, Taipei, Taiwan, ¹²National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: In primary Sjögren’s syndrome (pSS), the histologic focus score reflects immune infiltration but does not capture irreversible glandular damage. We evaluated a submandibular gland…
Abstract Number: 2416 • ACR Convergence 2025
Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Megan Barber¹, John Hanly², Murray Urowitz³, Ian Bruce⁴, Yvan St-Pierre⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Francisco Sanchez-Guerrero⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David A. Isenberg¹², Anisur Rahman¹², Joan Merrill¹³, Paul Fortin¹⁴, Dafna D. Gladman¹⁵, Michelle Petri¹⁶, Ellen Ginzler¹⁷, Mary Anne Dooley¹⁸, Rosalind Ramsey-Goldman¹⁹, Susan Manzi²⁰, Andreas Jönsen²¹, Graciela Alarcón²², Ronald van Vollenhoven²³, Cynthia Aranow²⁴, Meghan mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S. Sam Lim²⁷, Murat Inanç²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken⁸, Diane Kamen³¹, Anca Askanase³² and Ann Clarke¹, ¹Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, South Korea, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University Health Network/Sinai Health system, Toronto, ON, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²University College London, London, United Kingdom, ¹³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷SUNY Downstate Health Sciences University, New York, NY, ¹⁸UNC physician network, Chapel Hill, NC, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁰Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²¹Department of Clinical Sciences, Lund University, Lund, Sweden, ²²The University of Alabama at Birmingham, Oakland, CA, ²³Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ²⁴Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Biobizkaia Health Research Institute, Barakaldo, Spain, ²⁷Emory University School of Medicine, Atlanta, GA, ²⁸Istanbul University, Istanbul, Turkey, ²⁹UC San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹Medical University of South Carolina, Johns Island, SC, ³²Columbia University Medical Center, New York, NY
Background/Purpose: We reported partial direct healthcare costs associated with damage accrual in the SLICC Inception Cohort (Barber M. Arthritis Care Res 2020;72:1800). We have supplemented…
Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
RITESH KUMAR MISHRA¹, SUBIN PHILIP², JAIDEV MENON², RIZWANA NAUSHAD², AISHWARYA GOPAL³, CHRISTINA MARIASELVAM², Chengappa Kavadichanda², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…
Abstract Number: 2387 • ACR Convergence 2025
Lupus Damage Index Revision – Item Generation and Reduction Phases
Burak Kundakci¹, Megan Barber², Ann Clarke², Sindhu Johnson³ and Ian Bruce⁴, ¹Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ²Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom
Background/Purpose: The current Systemic Lupus Erythematosus Damage Index (SDI) is a robust instrument, but is limited by missing items, restricted applicability in pediatric patients, and…
Abstract Number: 2071 • ACR Convergence 2025
Impact of Diagnostic Delay on Disease Activity and Cumulative Damage in Patients with Idiopathic Inflammatory Myopathies in a Third-level Hospital in Mexico
valeria cantu¹, Rebeca L. Polina-Lugo¹, Emmanuel Dominguez-Chapa², Ana Cecilia Bardan Inchaustegui³, Fernanda M. Garcia-Carrillo⁴, Daniela A. Mejia-Rodriguez⁴, Ericka S. Reyna-Hernandez⁴, Rosa Arvizu-Rivera⁵, Jesus Alberto Cardenas-de la Garza⁶ and Miguel Villarreal-Alarcón⁷, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Hospital Universitario UANL, Monterrey, Nuevo León, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of autoimmune diseases marked by inflammation of muscle tissue and extramuscular manifestations. Their atypical…
Abstract Number: L13 • ACR Convergence 2024
Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort
Zahi Touma¹, Ian Bruce², Richard A. Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Kellyn Arnold⁸, Hopin Lee⁸, Eleanor Ralphs⁸, Danuta Kielar⁹, Aleksander Bedenkov⁹ and Miina Waratani⁹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²Queen's University Belfast, Belfast, United Kingdom, ³Northwell Health, Manhasset, NY, ⁴Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶Astrazeneca, Mississauga, ON, Canada, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸IQVIA, London, United Kingdom, ⁹Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In SLE, persistent disease activity, disease flares and long-term glucocorticoid (GC) use all contribute to organ damage accrual. The effects of novel therapies on…
Abstract Number: 2070 • ACR Convergence 2024
Increased Circulating Levels of Fatty Acid-binding Proteins as a Potential Biomarker of Disease Damage in Inflammatory Myopathies Patients
Margherita Giannini¹, Anne-Laure Charles², Julien Blaess³, Rose-Marie Javier⁴, Bernard Geny⁵ and Alain Meyer⁶, ¹UR3072, Physiology Department, University Hospital of Strasbourg, Strasbourg, France, ²UR3072, University of Strasbourg, Strasbourg, France, ³Physiology Department, University Hospital of Strasbourg, STRASBOURG, France, ⁴Rheumatology Department, University Hospital of Strasbourg, STRASBOURG, France, ⁵UR3072, Physiology Department, University Hospital of StrasbourgUniversity Hospital of Strasbourg, STRASBOURG, France, ⁶UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In inflammatory myopathies (IM), although several treatments effectively control disease activity, a high proportion of patients display sustained disability (damage). Damage might be reversed…
Abstract Number: 2308 • ACR Convergence 2024
Characterization of Damage in a Primary Sjogren’s Syndrome Cohort
Ana Mafalda Abrantes¹, Pedro Gaspar² and David Isenberg³, ¹Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Lisbon, Portugal, ²Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, ³University College London, London, United Kingdom
Background/Purpose: Damage is irreversible and represents a permanent loss in organ function. Outcome measures are critical for minimizing and prevent damage acquisition. There are two…
Abstract Number: 2309 • ACR Convergence 2024
Damage Accrual Predicts the Development of Lymphoma in Primary Sjogren’s Syndrome
Ana Mafalda Abrantes¹, Pedro Gaspar² and David Isenberg³, ¹Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Lisbon, Portugal, ²Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, ³University College London, London, United Kingdom
Background/Purpose: Primary Sjogren Syndrome (pSS) is an autoimmune disease affecting primarily exocrine glands. Over a quarter of patients have systemic involvement, which includes the development…
Abstract Number: 2318 • ACR Convergence 2024
Does the Time Interval Between the Onset of Psoriasis and Psoriatic Arthritis Impact Disease Presentation and Outcomes?
Fadi Kharouf¹, Pankti Mehta², Shangyi Gao², Daniel Pereira³, Richard Cook⁴, Dafna Gladman⁵ and Vinod Chandran⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Waterloo, Waterloo, Canada, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis typically precedes psoriatic arthritis (PsA), with a variable transition period. In this study, we aimed to explore whether the time interval between the…
Abstract Number: 2328 • ACR Convergence 2024
Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?
Fadi Kharouf¹, Virginia Carrizo Abarza², Shangyi Gao³, Daniel Pereira⁴, Richard Cook⁵, Vinod Chandran⁶ and Dafna Gladman⁷, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Waterloo, Waterloo, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Most patients with Psoriatic Arthritis (PsA) experience psoriasis (Ps) before the onset of arthritis. However, in about 15% of the cases, the skin and…
Abstract Number: 2374 • ACR Convergence 2024
Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia
Omer Uludag¹, Sarvan Aghamuradov¹, Cansu Erel Gezegen², Marjan Jabbarli², Ismat Habibov², Ahmet Oguz Celik², Yasemin Yalcinkaya¹, Ahmet Gul¹, Murat Inanc¹ and Bahar Artim Esen¹, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey
Background/Purpose: Thrombocytopenia has been reported at frequencies ranging from 10 to 40 % in different cohorts. Treatment can be challenging and due to its considerable…
Abstract Number: 0118 • ACR Convergence 2024
Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Erik Cimé-Aké¹, Gabriela Hernández-Molina², Amaya Llorente-Chávez³ and Eduardo Martin Nares², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Hematology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: The 2023 ACR/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) were recently published. The new criteria require an entry criterion and employe a…
Abstract Number: 2375 • ACR Convergence 2024
Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?
Burak Kundakci¹, Megan Barber², Ann E. Clarke², Sindhu Johnson³, Ian Bruce¹ and On behalf of the revised SLE organ damage index (SDI) collaborators⁴, ¹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ²Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: The Systemic Lupus International Collaborating Clinics (SLICC), Lupus Foundation of America (LFA), and American College of Rheumatology (ACR) are leading a global initiative to…
Abstract Number: 0122 • ACR Convergence 2024
Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome
Evelyn Aranda Cano¹, Jessica Roldan Ortega², Yaneli Juárez-Vicuña³, Fausto Sánchez Muñoz⁴, Itzel Palafox Sosa⁵, Luz Angelica Viruel-Mejia⁶, David Vera Bustamante⁷, Luis H. Silveira Torre⁸, Angélica Vargas Guerrero⁹, Mayra Nadia Quintanar-Cuevas¹⁰, Erick Giovanny Bautista Jímenez¹¹ and Laura Aline Martinez-Martinez¹², ¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Mexico, ²Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³Instituto Nacional del Cardiología Ignacio Chávez, México, Distrito Federal, Mexico, ⁴Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁵Escuela Superior de Medicina-Instituto Politecnico Nacional, Ciudad de México, Mexico, ⁶Rheumatology Departement at National Institute of Cardiology Ignacio Chavez - Universidad Autonoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, ⁷Benemerita Universidad Autonoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, ⁸Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁹Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ¹⁰Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, México, Mexico, ¹¹Hospital General de Zona No. 27 del Instituto Mexicano del Seguro Social, Mexico, Distrito Federal, Mexico, ¹²Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico
Background/Purpose: Growth differentiation factor 15 (GDF-15), is a stress induced inflammatory cytokine, member of the transforming growth factor-β superfamily, tissue injury. It is predominantly expressed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].